Tumor activated platelets induce vascular mimicry in mesenchymal stem cells and aid metastasis

Bhuniya, Avishek; Sarkar, Anirban; Guha, Aishwarya; Choudhury, Pritha Roy; Bera, Saurav; Sultana, Jasmine; Chakravarti, Mohona; Dhar, Shanta; Das, Juhina; Guha, Ipsita; Ganguly, Nilanjan; Banerjee, Saptak; Bose, Anamika; Baral, Rathindranath

doi:10.1016/j.cyto.2022.155998

Cited by 7 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the second population, although they were positive for platelet markers, the activation antigen (i.e., CD62P) was minimally expressed among patients showing a response (CR/PR) compared with non-responding patients. To date, growing evidence shows that platelet activation by cancer cells is the keystone toward a tumor-promoting phenotype [ 37 , 38 ]. Therefore, the reduction in platelet activation markers in B7-H3 Bright EVs derived from responders together with the inverse pattern of these vesicles among the patients at the first evaluation response (increased in responders and decreased in those who progress), support the hypothesis of B7-H3-EVs having a potential role in immune modulation.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Genova

Tasso

Rosa

et al. 2023

Cells

View full text Add to dashboard Cite

The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the advent of immune checkpoint inhibitors (ICIs). Despite encouraging results, their efficacy remains limited to a subgroup of patients. Circulating immune checkpoints in soluble (s) form and associated with extracellular vesicles (EVs) represent promising markers, especially in ICI-based therapeutic settings. We evaluated the prognostic role of PD-L1 and of two B7 family members (B7-H3, B7-H4), both soluble and EV-associated, in a cohort of advanced NSCLC patients treated with first- (n = 56) or second-line (n = 126) ICIs. In treatment-naïve patients, high baseline concentrations of sPD-L1 (>24.2 pg/mL) were linked to worse survival, whereas high levels of sB7-H3 (>0.5 ng/mL) and sB7-H4 (>63.9 pg/mL) were associated with better outcomes. EV characterization confirmed the presence of EVs positive for PD-L1 and B7-H3, while only a small portion of EVs expressed B7-H4. The comparison between biomarker levels at the baseline and in the first radiological assessment under ICI-based treatment showed a significant decrease in EV-PD-L1 and an increase in EV-B7H3 in patients in the disease response to ICIs. Our study shows that sPD-L1, sB7-H3 and sB7-H4 levels are emerging prognostic markers in patients with advanced NSCLC treated with ICIs and suggests potential EV involvement in the disease response to ICIs.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Genova

Tasso

Rosa

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…So far, platelet impact on MSCs’ capacity to support gastric cancer proliferation, migration, and metastasis in vitro and in vivo was shown [ 75 ], evidencing cancer cells and MSCs interplay in platelet activation, along with platelet-induced MSC transdifferentiation into cancer-associated fibroblast (CAF)-like cells through TGF-β production. In vitro and in vivo studies in mice melanoma model showed that tumor-educated platelets induced migration of MSCs to secondary metastatic site where they contribute to vessel-like structure formation (vascular mimicry), ultimately favoring metastasis process [ 76 ]. Also, the role of TSP-1/TGF-β1 axis in platelets interactions with bone marrow cells was found to contribute to pre-metastatic niche formation and tumor-induced bone turnover in murine model of prostate cancer [ 34 ].…”

Section: Interplay Of Platelets and Stromal Cellsmentioning

confidence: 99%

Revealing profile of cancer-educated platelets and their factors to foster immunotherapy development

Trivanović,

Mojsilović,

Bogosavljević

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

“…Bhunija et al indicated that tumour-activated platelets bind to MSCs in the tumour's microenvironment, inducing the so-called vascular mimicry (VM). It is a term for the formation of pseudo-vascular structures by cancer cells [15]. Another lately popular investigated mechanism is the SDF-1/CXCR4 and its role in tumour progression.…”

Section: Mscs In Prostate and Bladder Cancer Researchmentioning

confidence: 99%

MSCs and CAFs interactions in the prostate and bladder cancer microenvironment as the potential cause of tumour progression

Balik

Kaźmierski

Maj

et al. 2023

Medical Research Journal

View full text Add to dashboard Cite

The tumour microenvironment (TME) is the broadly understood environment around the tumour.Cancer-associated fibroblasts (CAFs), Mesenchymal Stromal Cells (MSCs), and molecules synthesized by them are part of it. Both CAFs and MSCs can promote tumour progression by induction of an immunosuppressive, pro-inflammatory environment. Through indirect and direct cell-to-cell interactions they also have a pro-proliferative, pro-angiogenic, and pro-invasive effect on cancer cells.They can lead to aggressive cancer formation. At this stage, it is important to conduct research to modulate TME towards inhibition of cancer progression and preventing resistance to already introduced drugs. Moreover, it is extremely important to study these interactions in light of using MSCs in a drug-delivery strategy.

show abstract

Tumor activated platelets induce vascular mimicry in mesenchymal stem cells and aid metastasis

Cited by 7 publications

References 28 publications

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Revealing profile of cancer-educated platelets and their factors to foster immunotherapy development

MSCs and CAFs interactions in the prostate and bladder cancer microenvironment as the potential cause of tumour progression

Contact Info

Product

Resources

About